TempraMed CenterWell Pharmacy Distribution Agreement
Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The deal is a small-cap commercial milestone for TempraMed, potentially improving its U.S. distribution reach and revenue prospects, though the absence of minimum purchase commitments limits near-term earnings visibility. For Humana, the impact is marginal, as CenterWell Pharmacy adding another supplier of medication-storage devices is unlikely to materially move its financials or stock.
TempraMed Technologies, a Canadian medical-device company trading on the CSE under VIVI, announced it entered into a distribution agreement dated August 25, 2026 with CenterWell Pharmacy, the pharmacy services brand of U.S. health insurer Humana Inc. Under the agreement, CenterWell Pharmacy is expected to distribute TempraMed's temperature-controlled medication-storage products, including VIVI Cap and VIVI Epi, in the United States. TempraMed describes itself as a global medical-device company whose patented, FDA-registered thermal-insulation devices operate without batteries or external power, designed to protect temperature-sensitive medications. The agreement contains no minimum purchase commitments, and either party may terminate it on 60 days prior written notice. TempraMed framed the deal as a step to expand its commercial presence in the United States, while cautioning that there is no assurance orders will be placed or revenue generated. The announcement was issued via press release and carried by multiple outlets on September 23, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard